Johnson & Johnson continues to attract investors with its leaner business model focused on innovative medicine and medical technology after spinning off Kenvue. The company raised its dividend by 3.1%, marking 64 years of consecutive growth, supported by $19.7 billion in free cash flow and a AAA credit rating. Q1 2026 results showed nearly 10% revenue growth and raised full-year guidance, driven by strong sales in key drugs like DARZALEX and TREMFYA. Despite challenges from biosimilars affecting STELARA and ongoing talc litigation, J&J's robust pipeline, aging global population trends, and financial strength make it a compelling long-term buy.
A recent study by Spherix Global Insights highlights the unmet need for new treatments in warm autoimmune hemolytic anemia (w-AIHA), especially beyond second-line therapies where no clear standard exists. Current treatments rely heavily on corticoste...
Johnson & Johnson announced that its drug IMAAVY (nipocalimab-aahu) achieved a significant and durable hemoglobin response in patients with warm autoimmune hemolytic anemia (wAIHA) during a Phase 2/3 trial. Patients receiving the 30 mg/kg dose showed...
With interest rates stabilizing in mid-2026, investors are focusing on Dividend Kings and Aristocrats known for decades of consecutive dividend increases. Johnson & Johnson, Coca-Cola, and McDonald's stand out for their strong Q1 earnings, reasonable...
The SNPD ETF focuses on companies with long histories of increasing dividends, such as Johnson & Johnson, Coca-Cola, Procter & Gamble, PepsiCo, and Lowe's. These companies have strong free cash flow coverage supporting their payouts, making SNPD's di...
Healthcare ETFs provide a blend of defensive stability and growth potential by covering broad healthcare sectors and specialized themes like biotechnology, pharmaceuticals, and weight-loss treatments. Aging populations and rising healthcare demand su...
